102 related articles for article (PubMed ID: 26524031)
1. [Relationship between Chemotactic Factor CCL5 and Diabet-associated Diffuse Large B Cell Lymphoma].
Zhang JC; Liu FR; Hu HX; He F; Tu Y; Wei B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1325-30. PubMed ID: 26524031
[TBL] [Abstract][Full Text] [Related]
2. Diabetes mellitus potentiates diffuse large B‑cell lymphoma via high levels of CCL5.
Zhang J; Luo J; Liu F; Wu D; Zhong Q; Zeng L; Wu Z; Zhao T; Wu L; Hao H
Mol Med Rep; 2014 Sep; 10(3):1231-6. PubMed ID: 24938715
[TBL] [Abstract][Full Text] [Related]
3. Analysis of CCL5 expression in classical Hodgkin's lymphoma L428 cell line.
Liu F; Zhang Y; Wu ZQ; Zhao T
Mol Med Rep; 2011; 4(5):837-41. PubMed ID: 21701779
[TBL] [Abstract][Full Text] [Related]
4. [Establishment and characterization of a nude mice model of human diffuse large B-cell lymphoma].
Yu BH; Zhou XY; Zhang TC; Zhang TM; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):246-50. PubMed ID: 21615998
[TBL] [Abstract][Full Text] [Related]
5. [Immuno-characterization of mouse model similar to human diffuse large B cell lymphoma].
Liu F; Zhang G; Zhou XH; Liu J; Yue Y; Zhao T
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):655-9. PubMed ID: 20561422
[TBL] [Abstract][Full Text] [Related]
6. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
[No Abstract] [Full Text] [Related]
7. [SUDHL-4 cell culture in vitro and establishment of mouse tumor model].
Wang YQ; Huo HJ; Lu LL; Xu M; Zhu JP; Wang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):329-34. PubMed ID: 22541092
[TBL] [Abstract][Full Text] [Related]
8. [Ibrutinib inhibits mesenchymal stem cells-mediated drug resistance in diffuse large B-cell lymphoma].
Wu L; Zhang YZ; Xia B; Li XW; Yuan T; Tian C; Zhao HF; Yu Y; Sotomayor E
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1036-1042. PubMed ID: 29365396
[No Abstract] [Full Text] [Related]
9. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.
Pham LV; Bryant JL; Mendez R; Chen J; Tamayo AT; Xu-Monette ZY; Young KH; Manyam GC; Yang D; Medeiros LJ; Ford RJ
Oncotarget; 2016 Dec; 7(49):80599-80611. PubMed ID: 27716624
[TBL] [Abstract][Full Text] [Related]
10. [Production and mechanism of CCL5 by macrophages in U14 cervical cancer-bearing mice during infection].
Ren H; Ren G; Sun L; Fan X; Wang Y; Li X
Zhonghua Fu Chan Ke Za Zhi; 2015 May; 50(5):367-73. PubMed ID: 26311457
[TBL] [Abstract][Full Text] [Related]
11. [Effects of 2-12alkyl-6-methoxycyclohexa-2, 5-diene-1, 4-dione(DMDD)on diffuse large B lymphoma and its mechanism].
Hong K; Jiang PR; Ke RJ; Ying JH; Zhang XY; Chen JY
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2019 Jul; 35(4):312-316. PubMed ID: 31701713
[TBL] [Abstract][Full Text] [Related]
12. Preliminary study on decreasing the expression of FOXP3 with miR-155 to inhibit diffuse large B-cell lymphoma.
Zhang J; Wei B; Hu H; Liu F; Tu Y; Zhao M; Wu D
Oncol Lett; 2017 Aug; 14(2):1711-1718. PubMed ID: 28789399
[TBL] [Abstract][Full Text] [Related]
13. PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.
Cui W; Zheng S; Li X; Ma Y; Sang W; Liu M; Zhang W; Zhou X
Tumour Biol; 2016 Sep; 37(9):12767-12777. PubMed ID: 27448819
[TBL] [Abstract][Full Text] [Related]
14. ALPK1 regulates streptozotocin-induced nephropathy through CCL2 and CCL5 expressions.
Lee CP; Nithiyanantham S; Hsu HT; Yeh KT; Kuo TM; Ko YC
J Cell Mol Med; 2019 Nov; 23(11):7699-7708. PubMed ID: 31557402
[TBL] [Abstract][Full Text] [Related]
15. [Activation and clinicopathologic significance of AKT/mTOR signaling pathway in diffuse large B-cell lymphoma].
Yu BH; Zhou XY; Xiao XY; Yan SY; Qin T; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):35-41. PubMed ID: 19489223
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
[TBL] [Abstract][Full Text] [Related]
17. [In vitro effect of alendronate on chondrocytes and articular cartilage and subchondral bone in rabbit anterior cruciate ligament transection model].
Hu H; Zhang L; Li B; Zhang Y; Liu X; Tian F; Cheng T; Wang Z
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2009 Dec; 23(12):1474-81. PubMed ID: 20073314
[TBL] [Abstract][Full Text] [Related]
18. MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.
Wang WG; Jiang XN; Liu ZB; Zhou XY; Li XQ
Am J Surg Pathol; 2017 Apr; 41(4):541-549. PubMed ID: 28291124
[TBL] [Abstract][Full Text] [Related]
19. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
[TBL] [Abstract][Full Text] [Related]
20. Stem cell characteristics promote aggressiveness of diffuse large B-cell lymphoma.
Chang KC; Chen RY; Wang YC; Hung LY; Medeiros LJ; Chen YP; Chen TY; Yang JC; Chiang PM
Sci Rep; 2020 Dec; 10(1):21342. PubMed ID: 33288848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
